icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm

Germany approves first clinical trial for potential Covid-19 vaccine

Germany approves first clinical trial for potential Covid-19 vaccine
Germany has sanctioned its first clinical trial of a potential vaccine for the novel coronavirus, the country’s Paul-Ehrlich-Institut (PEI) regulatory body has said.

The authorization is the result of “careful assessment of the potential risk/benefit profile of the vaccine candidate,” the medical institute said in a statement on Wednesday.

The potential vaccine, named BNT162, was developed by German biotech company BioNTech with US pharma giant Pfizer. 

The German trial will be conducted on 200 healthy people between the ages of 18 and 55 in its first stage. After an observational waiting period, more volunteers in the same age range will be vaccinated. It will then be trialed on people who are at a higher risk of Covid-19 infection.

Also on rt.com Covid-19 mutations underestimated, Chinese scientists warn, as DEADLIEST strains grip Europe and US

Tests of the BNT162 vaccine are also planned in the US and will begin when regulatory approval for human testing is secured there.

“First clinical trials aim at investigating the general tolerability of vaccine candidates as well as their ability to induce a specific immune response against the pathogen,” the PEI said in the statement.

The German trial is the fourth authorized human clinical trial for a Covid-19 vaccine worldwide. The PEI said it assumes that further trials for a vaccine will begin in Germany in the next few months.

Like this story? Share it with a friend!

Dear readers and commenters,

We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.

Sorry for the inconvenience, and looking forward to your future comments,

RT Team.

Podcasts